Inclusion Criteria:

          -  Voluntary informed consent for entry of trial;

          -  Age greater than 18 years, and less than 70 years;

          -  Pathologically confirmed recurrent malignant gliomas;

          -  Tumor cells from resected tissue must be available for antigen testing (EGFRvIII,
             IL13Rα2, Her-2, CD133, EphA2, GD2) and at least one of the targets should be tested
             positively by immunohistochemistry study;

          -  If the patient is on dexamethasone, the anticipated dose must be 4 mg/day or less for
             at least 5 days prior to apheresis.

          -  Patients must have a Karnofsky performance status of greater than or equal to 70.

          -  Life expectancy greater than 3 months;

          -  Participants with adequate organ function as measured by:

               1. White blood count greater than or equal to 2500/mm^3; platelets greater than or
                  equal to 100,000/mm^3, hemoglobin greater than or equal to 10.0 g/dL; without
                  transfusion or growth factor support

               2. Aspartate transaminase (AST), Alanine transaminase (ALT), gamma glutamyl
                  transpeptidase (GGT), lactic acid dehydrogenase (LDH), alkaline phosphatase
                  within 2.5 x upper normal limit, and total bilirubin less than or equal to 2.0
                  mg/dL

               3. Serum creatinine less than or equal to 1.5 x upper limit of normal

               4. Coagulation tests prothrombin time (PT) and partial thromboplastin time (PTT)
                  have to be within normal limits, unless the patient has been therapeutically
                  anti-coagulated for previous venous thrombosis.

        Exclusion Criteria:

          -  Female subjects of reproductive potential who are pregnant or lactating;

          -  Previous treatment with any gene therapy products or other form immunotherapy;

          -  Uncontrolled active infection.

          -  Active or latent chronic hepatitis B [detectable hepatitis B surface antigen (HBsAg)]
             or active hepatitis C (positive serology [hepatitis C virus Ab]) infection.

          -  HIV infection;

          -  History of allergy or hypersensitivity to study product excipients (human serum
             albumin, Dimethyl sulfoxide, and Dextran 40);

          -  Currently enrolled in other clinical trials;